- Lobbying
- for AND clinical AND oncology
Lobbying Arrangements Results for 'For Clinical Oncology'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details HR 913 - Clinical Treatment Act, drug pricing issues |
Peck Madigan Jones (on behalf of American Society of Clinical Oncology)
|
Tiber Creek Health Strategies, Inc. | |||
Details H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act |
Peck Madigan Jones (on behalf of Association for Clinical Oncology)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to oncology care, physician reimbursement, research funding, and the cost of prescription drugs. CLINICAL TREATMENT Act, HR 913. Issues related to oncology care, physician reimbursem... |
American Society of Clinical Oncology
|
Peck Madigan Jones | |||
Details Appropriations issues related to Pediatric cancer research Issues related to funding for pediatric cancer research. |
Pediatric Neuro-Oncology Consortium Foundation
|
TOWER 19 | |||
Details H. Con. Res. 96-- Establishing the budget for the U.S. Government for FY 2015 and setting forth appropriate budgetary levels for FY 2016 through 2024 In all of the above the specific issues include... |
Millennium: The Takeda Oncology Company
|
in-house lobbying | |||
Details Hematology and hematology/oncology public health and research issues; HR 640 Bone Marrow Failure Disease Research and Treatment Act of 2011. Medicare Physician Fee Schedule; Medicare Reimbursement... |
American Society of Hematology
|
HOLLAND & KNIGHT LLP | |||
Details Palliative Care and Hospice Education and Training Act (PCHETA) (S.2243), Cancer Drug Parity Act (S.2039/H.R. 6301), Improving Care and Access to Nurses (H.R.2713/S. 2418), No Tax Subsidies for E-C... |
Oncology Nursing Society
|
in-house lobbying | |||
Details Medicare Regulations, Reimbursement issues, Cancer Treatment Cancer Treatment |
VANTAGE ONCOLOGY
|
BUCHANAN INGERSOLL & ROONEY PC | |||
Details FY2024 LHHS Appropriations bill-funding for NIH/NCI Access to radioactive isotopes Support to ensure that advances in biomedical research impacting patient care are not compromised by any policies ... |
AMERICAN SOCIETY FOR RADIATION ONCOLOGY
|
in-house lobbying | |||
Details H.R. 6331 (Medicare Improvements for Patients and Providers Act of 2008), Medicare Part B payments for drugs subject to ASP methodology |
US Oncology
|
Arent Fox LLP | |||
Details Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transpare... |
Association for Clinical Oncology
|
Tiber Creek Group | |||
Details Medicare policy issues relating to consolidated billing for lab services. |
RedPath Integrated Pathology, Inc.
|
KING & SPALDING LLP | |||
Details HR 913 - CLINICAL TREATMENT Act Implementation of the Medicare Access and CHIP Re authorization Act HR 3107 Improving Seniors' Timely Access to Care Act of 2019 Funding for the National Institute ... |
American Society of Clinical Oncology
|
in-house lobbying | |||
Details Discussions regarding patient access to radiation oncology. |
American Society for Radiation Oncology
|
Cornerstone Government Affairs, Inc. | |||
Details Issues pertaining to the federal government's regulation and coverage of cancer care and treatments [Comprehensive Cancer Care Improvement Act (H.R. 1078) -- all provisions; Legislation pertaining ... |
American Society of Clinical Oncology
|
POWELL GOLDSTEIN LLP | |||
Details Legislative and regulatory matters related to Medicare reimbursement for oncology treatment, drugs, and decision support tools. Centers for Medicare and Medicaid Innovation (CMMI) Oncology Care Mo... |
UPMC CancerCenter
|
Hooper, Lundy & Bookman, P.C. | |||
Details address CMMI payment models like the RO Model and prior authorization process for Medicare beneficiaries Address payment models that impact reimbursement for proton therapy and prior authorization ... |
Proton Therapy Consortium FKA NATIONAL ASSOCIATION FOR PROTON THERAPY
|
in-house lobbying | |||
Details Newborn Screening Quality Assurance Program at CDC; Newborn Screening Implementation Proposal at HRSA. Funding for Newborn Screening Quality Assurance Program at CDC; Newborn Screening Program at H... |
Biogen
|
NVG, LLC | |||
Details H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S... |
McKesson Corporation & affiliates U.S. Oncology and Rx Savings Solutions
|
McKesson Corporation & affiliates U.S. Oncology and Rx Savings Solutions (Formerly McKesson Corp) | |||
Details Prepared comments on the Centers for Medicare and Medicaid Services data request and access policy changes; Prepared comments on the Food and Drug Administrations Draft Guidance for Industry and Fo... |
Physician Clinical Registry Coalition
|
Powers Pyles Sutter & Verville, P.C. | |||
Details Medicare and Medicaid Policy Health Issues Alzheimer's Disease Legislation |
MGI PHARMA, INC.
|
in-house lobbying | |||
Details Improving Cancer Education Act (H.R. 1661). |
Oncology Nursing Society
|
DRINKER BIDDLE & REATH LLP | |||
Details Drug price monitoring; H.R. 1730, S. 741 The Cancer Drug Parity Act. S. 551 The REFUND Act; Provider status for pharmacists. |
Hematology/Oncology Pharmacy Association
|
DRINKER BIDDLE & REATH LLP | |||
Details Issues related to the quality of cancer care; Health reform implementation issues pertaining to the regulation and coverage of cancer care and treatments; Issues pertaining to average sales price;I... |
American Society of Clinical Oncology
|
Polsinelli PC | |||
Details Pharmaceutical Manufacturing; Pharmacy Issues; Clinical Pharm-Assist; Medicare Prescription Drug Benefits; American's Health Choices Act, Regulations under MMA re: Medicare Prescription Drug Benef... |
New Century Health
|
DUMBARTON GROUP, LLC | |||
Details Issues related to development of oncology treatments |
Spectrum Pharmaceuticals, Inc.
|
JEFFREY J. KIMBELL & ASSOCIATES, INC. | |||
Details FY 2009 Labor, HHS, Education Appropriations Bills Hematology Research Medicare Physician Fee Schedule Medicare Reimbursement for Drugs and Biologicals Medicare Coverage Policies Medicare Hospital ... |
AMERICAN SOCIETY OF HEMATOLOGY
|
MARC ASSOCIATES, INC. | |||
Details Advocate for client before members of the U.S. House of Representatives, U.S. Senate, and staffs to each, and before the Department of Health and Human Services, sub-agencies, and staffs to each, w... |
Novocure Inc.
|
Rubin and Rudman LLP | |||
Details Federal support for next generation COVID-19 vaccine technology research, development and manufacturing, approval and distribution. Federal support for next generation COVID-19 vaccine technology r... |
ImmunityBio, Inc.
|
The Petrizzo Group, Inc. | |||
Details Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory work... |
Quest Diagnostics Incorporated
|
in-house lobbying | |||
Details - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Di... |
Foundation Medicine, Inc.
|
in-house lobbying | |||
Details H.R. 1427-Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548-Pathway for Biosimilars Act S. 726-Promoting Innovation Access to Life-Saving Medicine Act The Affordable Health Choi... |
Millennium: The Takeda Oncology Company
Pharmaceutical manufacturing |
POLICY IMPACT COMMUNICATIONS, INC. | |||
Details Issues related to coverage and reimbursement of pharmaceutical products. Issues related to screening and treatment of hepatitis C, oncology and rheumatoid arthritis. Coverage of pharmaceuticals, co... |
AbbVie Inc.
|
Thorn Run Partners | |||
Details Pharmaceutical Manufacturing; Pharmacy Issues; Clinical Pharm-Assist; Medicare Prescription Drug Benefits; American's Health Choices Act (HR 3200), Regulations under MMA re: Medicare Prescription ... |
Strativa Pharmaceuticals
|
DUMBARTON GROUP & ASSOCIATES, LLC | |||
Details Issues related to the quality of cancer care [Patient Protection and Affordable Care Act (H.R. 3590); Affordable Health Care for America Act (H.R. 3962); Mammogram and MRI Availability Act (H.R. 99... |
American Society of Clinical Oncology
|
Bryan Cave LLP | |||
Details Advocated for increased funding for NIH and NCI. Advocated for precision medicine and precision oncology issues. Advocated for clinical research administrative reforms. Advocated against any reduct... |
Fred Hutchinson Cancer Research Center
|
The Petrizzo Group, Inc. | |||
Details S 765/HR 1526: Reducing Hereditary Cancer Act of 2023- provide hereditary cancer genetic testing Increasing access to telehealth S 2016/HR 4189: CONNECT for Health Act- expands access to telehealth... |
ASSOCIATION FOR CLINICAL ONCOLOGY
|
in-house lobbying | |||
Details advocate on and monitor any congressional legislation and activity as it relates to cancer monitoring, diagnosis, and treatment; including clinical laboratories, bio markertesting, health care cove... |
Guardant Health
|
Cassidy & Associates, Inc. | |||
Details Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) FY 2024 NIH funding FY 2024 AHRQ funding FY 2024 CDC funding FY 2024 funding for CDC Sic... |
American Society of Hematology
|
in-house lobbying | |||
Details Funding related to biomedical and cancer research and innovation at the NIH and NCI, funding for Childhood Cancer research, funding for ARPA-H in the Labor, Health and Human Services, Education bil... |
Dana-Farber Cancer Institute
|
in-house lobbying | |||
Details International trade and protection of intellectual property; TRIPS Waiver; the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries. Advocate on drug ... |
GILEAD SCIENCES, INC.
|
in-house lobbying | |||
Details Legislative and regulatory matters related to physician reimbursement for and patient access to radiation oncology treatment; including implementation of related provisions in H.R. 2029, Consolidat... |
Varian Medical Systems
|
Capitol Counsel LLC |